Manhattan BioSolutions, Inc. was founded in 2018 by Dr Borys Shor and Prof. Yossef Av-Gay at University of British Columbia, Vancouver, Canada, with a core mission to unlock the natural ability of the human innate immune system to defend the body against the invading pathogens or cancer. The initial focus of Manhattan Bio was the development of synthetic live medicines specifically designed to target the unique mutations found in cancer cells, provoking a potent and tailored immune response against the tumors. Manhattan BioSolutions has achieved significant preclinical proof of concept data, providing compelling evidence of the efficacy and potential of this innovative approach. As the company evolved, it explored the potential of other remarkable protective mechanisms governing immune defense and homeostasis within the body, with the aim of developing novel therapeutics.
In 2018, our startup has won the prestigious Johnson & Johnson Innovation QuickFire Challenge Competition and the accompanying award, granting us free laboratory and office space at the newly opened JLabs@NYC incubator in downtown Manhattan. Our current R&D laboratory is located in Manhattan, New York, is designed for in-house pre-clinical discovery including protein or antibody high-throughout screening and functional in vitro cellular assays. We also partner with Gilman Biosciences headed Dr. Babic, to externalize preclinical assay development, leveraging his expertise and track record in translational drug discovery.
Establishing a track record of success, Manhattan BioSolutions has been awarded grants and awards from various prestigious organizations, including the New Jersey CSIT, the University at Buffalo Center for Advanced Technology in Big Data and Health Sciences, the National Science Foundation, the National Cancer Institute, and the New York State Center for Biotechnology at Stony Brook University, further bolstering our innovative research and development efforts